Sierra Oncology

June 05, 2019

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.

Does amount matter when it comes to a biotech IPO?

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Lilly scraps two research assets, leaving few rivals behind

Where is the IPO class of 2014-15 now?

Select small caps stand out amid wider 2016 stock market declines

Patience rewards Ionis and Ziarco

Returns hint at gradual decline in quality of biotech floats

Lively M&A scene keeps biotech shares buoyant in Q3

Genmab and Tesaro lead first-half gainers as Endo and Infinity falter

Bristol-Myers buys back Medarex discard

Asco event analyser – 2016’s winners and losers

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

Evaluate Vantage COVID-19 Report

Editor's Picks

Finding the next Vertex

Clinical setback lays bare Vertex’s weakness

SITC 2020 – embargo snafu triggers the first movers

Biopharma buyouts still pricey

More biotechs test the third way to market